EU/3/19/2209

Table of contents

About

On 17 October 2019, orphan designation EU/3/19/2209 was granted by the European Commission to Biopharma Excellence GmbH, Germany, for anti-neonatal Fc receptor human monoclonal antibody (also known as M281) for the prevention of haemolytic disease of the foetus and newborn.

Key facts

Active substance
Anti-neonatal Fc receptor human monoclonal antibody
Disease / condition
Prevention of haemolytic disease of the foetus and newborn
Date of first decision
17/10/2019
Outcome
Positive
EU designation number
EU/3/19/2209

Sponsor's contact details

Biopharma Excellence GmbH
C/o Munich Technology Center
Agnes-Pockels-Bogen 1
Bavaria
80992 Munich
Germany
Tel: +49 (0)89-5505089 0
E-mail: info@biopharma-excellence.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating